These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32436725)

  • 1. Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis).
    Zhang T; Xu L; Tang X; Wei Y; Hu Q; Hu Y; Cui H; Tang Y; Hui L; Li C; Cao L; Lu Z; Wang J
    Aust N Z J Psychiatry; 2020 Jul; 54(7):696-706. PubMed ID: 32436725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.
    Zhang T; Wang J; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Li C; Ling Z; Wang J
    Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):591-602. PubMed ID: 34536114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study.
    Zeng J; Raballo A; Gan R; Wu G; Wei Y; Xu L; Tang X; Hu Y; Tang Y; Chen T; Li C; Wang J; Zhang T
    J Clin Psychiatry; 2022 Mar; 83(3):. PubMed ID: 35324095
    [No Abstract]   [Full Text] [Related]  

  • 4. Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk: A Systematic Review and Meta-Analysis.
    Raballo A; Poletti M; Preti A
    JAMA Psychiatry; 2024 Jul; 81(7):727-730. PubMed ID: 38506802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When to initiate antipsychotic treatment for psychotic symptoms: At the premorbid phase or first episode of psychosis?
    Zhang T; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Xie B; Li C; Wang J
    Aust N Z J Psychiatry; 2021 Mar; 55(3):314-323. PubMed ID: 33143440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year follow-up of a Chinese sample at clinical high risk for psychosis: timeline of symptoms, help-seeking and conversion.
    Zhang TH; Li HJ; Woodberry KA; Xu LH; Tang YY; Guo Q; Cui HR; Liu XH; Chow A; Li CB; Jiang KD; Xiao ZP; Seidman LJ; Wang JJ
    Epidemiol Psychiatr Sci; 2017 Jun; 26(3):287-298. PubMed ID: 27056022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic and functional remission of subjects at clinical high risk for psychosis: a 2-year naturalistic observational study.
    Lee TY; Kim SN; Correll CU; Byun MS; Kim E; Jang JH; Kang DH; Yun JY; Kwon JS
    Schizophr Res; 2014 Jul; 156(2-3):266-71. PubMed ID: 24815568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2).
    Wu G; Gan R; Li Z; Xu L; Tang X; Wei Y; Hu Y; Cui H; Li H; Tang Y; Hui L; Liu X; Li C; Wang J; Zhang T
    Neuropsychiatr Dis Treat; 2019; 15():3541-3548. PubMed ID: 31920314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of conversion rates, clinical profiles and predictors of outcomes in two independent samples of individuals at clinical high risk for psychosis in China.
    Li H; Zhang T; Xu L; Tang Y; Cui H; Wei Y; Tang X; Woodberry KA; Shapiro DI; Li C; Seidman LJ; Wang J
    Schizophr Res; 2018 Jul; 197():509-515. PubMed ID: 29287626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analyzing the prevalence and prognostic effect of antipsychotic exposure in clinical high-risk (CHR): when things are not what they seem.
    Raballo A; Poletti M; Preti A
    Psychol Med; 2020 Dec; 50(16):2673-2681. PubMed ID: 33198845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized risk components guiding antipsychotic delivery in patients with a clinical high risk of psychosis: application of a risk calculator.
    Zhang T; Xu L; Li H; Cui H; Tang Y; Wei Y; Tang X; Hu Y; Hui L; Li C; Niznikiewicz MA; Shenton ME; Keshavan MS; Stone WS; Wang J
    Psychol Med; 2021 Feb; ():1-10. PubMed ID: 33593473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic interventions in prodromal psychosis: safety issues.
    Liu CC; Demjaha A
    CNS Drugs; 2013 Mar; 27(3):197-205. PubMed ID: 23436256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis.
    Raballo A; Poletti M; Preti A
    Transl Psychiatry; 2023 Apr; 13(1):112. PubMed ID: 37019886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk.
    Cannon TD; Chung Y; He G; Sun D; Jacobson A; van Erp TG; McEwen S; Addington J; Bearden CE; Cadenhead K; Cornblatt B; Mathalon DH; McGlashan T; Perkins D; Jeffries C; Seidman LJ; Tsuang M; Walker E; Woods SW; Heinssen R;
    Biol Psychiatry; 2015 Jan; 77(2):147-57. PubMed ID: 25034946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of Untreated Prodromal Psychosis and Cognitive Impairments.
    Zhang T; Cui H; Wei Y; Tang X; Xu L; Hu Y; Tang Y; Liu H; Wang Z; Chen T; Li C; Wang J
    JAMA Netw Open; 2024 Jan; 7(1):e2353426. PubMed ID: 38277145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: Findings from the Parma At-Risk Mental States (PARMS) program.
    Pelizza L; Leuci E; Quattrone E; Azzali S; Paulillo G; Pupo S; Poletti M; Raballo A; Pellegrini P; Menchetti M
    Early Interv Psychiatry; 2024 Feb; 18(2):71-81. PubMed ID: 37194411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial.
    McFarlane WR; Levin B; Travis L; Lucas FL; Lynch S; Verdi M; Williams D; Adelsheim S; Calkins R; Carter CS; Cornblatt B; Taylor SF; Auther AM; McFarland B; Melton R; Migliorati M; Niendam T; Ragland JD; Sale T; Salvador M; Spring E
    Schizophr Bull; 2015 Jan; 41(1):30-43. PubMed ID: 25065017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtypes of Clinical High Risk for Psychosis that Predict Antipsychotic Effectiveness in Long-Term Remission.
    Zhang T; Wang J; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Hui L; Li C; Wang J
    Pharmacopsychiatry; 2021 Jan; 54(1):23-30. PubMed ID: 33045753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study.
    Zhang T; Li H; Woodberry KA; Seidman LJ; Zheng L; Li H; Zhao S; Tang Y; Guo Q; Lu X; Zhuo K; Qian Z; Chow A; Li C; Jiang K; Xiao Z; Wang J
    Schizophr Res; 2014 Feb; 152(2-3):391-9. PubMed ID: 24387999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.